A new study by Dr Ruth Dobson and colleagues at Queen Mary University London found that people with MS had higher levels of vitamin D than people without MS, because they were more likely to take a supplement.
The results from our Phase 2a clinical trial have shown that bexarotene is capable of regenerating lost myelin – the protective coating that surrounds nerve fibres, which is damaged in MS. Now, a new trial of the diabetes drug metformin will build on this work.
Women with MS often report fewer symptoms during pregnancy. But studies exploring whether becoming pregnant or having children affects whether or when someone develops MS have so far been inconclusive. Now, the biggest study yet suggests pregnancy may be linked to a delay in experiencing one of the early signs of MS.
Findings from a UK survey show that during the early phase of the pandemic, when strict lockdown measures were taken, people with MS had a similar chance of getting coronavirus to the general population. The data reinforces that self-isolating greatly decreased the risk of coronavirus.
The European Medicines Agency (EMA) has approved a shorter two-hour infusion time for people taking ocrelizumab (Ocrevus). The new guidance applies to people taking ocrelizumab for relapsing MS or primary progressive MS